BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-722 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-722\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07904754-11133@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:ABBV-722: Phase 2 readout est. (NCT07904754)
DESCRIPTION:ABBV-722\, phase 2.\nStudy: Platform Study of Targeted Therapie
 s for Adults With Moderately to Severely Active Rheumatoid Arthritis\nEsti
 mated primary completion: July 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abbv-722#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07904754
URL:https://assetmemo.bio/drug/abbv-722#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933211-11133@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20350630
DTEND;VALUE=DATE:20350701
SUMMARY:ABBV-722: Phase 2/3 readout est. (NCT07933211)
DESCRIPTION:ABBV-722\, phase 2/3.\nStudy: A Study to Evaluate the Safety an
 d Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Part
 icipants With Systemic Sclerosis That Are Currently Receiving Local Standa
 rd of Care Treatment\, and to Determine the Best Dose of ABBV-2294 to be E
 valuated Further.\nEstimated primary completion: June 2035. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/abbv-722#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07933211
URL:https://assetmemo.bio/drug/abbv-722#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
